Drug intelligence / Profile preview

SBRX8

Development stage: Preclinical
Lead developer: Stramsen Biotech

Overview

SBRX8 is a plant-based drug candidate being developed by Stramsen Biotech for the treatment of sickle cell disease. It is part of the company's SBRX series of botanical-derived therapeutics. While the specific molecular targets and mechanism of action have not been publicly disclosed, the drug is positioned as a natural-product-based intervention for hematological disorders. As of the current pipeline status, SBRX8 is in the early stages of development, with no specific clinical phase information provided by the developer.

Beyond the preview

Go deeper on SBRX8.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBRX8.

Explore the full profile